Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported a compensation-related share disposition. On the vesting of restricted stock units, 6,529 shares of common stock were delivered on June 8, 2026 solely to cover income taxes at $1.33 per share. After this tax-withholding event, Mitchell directly holds 102,949 MYO shares.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported a routine tax-related share disposition. On June 8, 2026, 7,635 shares of common stock were sold at $1.33 per share solely to cover income taxes from restricted stock units that vested on June 5, 2026. After this transaction, he directly holds 100,983 shares.
MYOMO, INC. Chief Financial Officer David A. Henry had 10,050 shares of common stock withheld on June 8, 2026 to cover income taxes from restricted stock units that vested on June 5, 2026. After this tax-withholding disposition, he directly holds 435,124 shares of MYO common stock.
MYOMO, INC. director F. Kirk Thomas reported an open-market purchase of 40,002 shares of common stock on June 5, 2026 at a weighted average price of $1.27 per share. The filing notes the shares were bought in multiple lots at prices ranging from $1.23 to $1.30 per share. Following this transaction, Thomas directly owns 693,865 shares of Myomo common stock.
MYOMO, INC. Chief Commercial Officer Micah Mitchell sold 90,231 shares of common stock in open-market transactions on May 14, 2026. The weighted average sale price was $0.861 per share, with individual lots ranging from $0.85 to $0.889 per share. After these sales, Mitchell directly holds 109,478 shares of MYOMO common stock.
Myomo, Inc. filed a Rule 144 notice reporting planned sales of Common Stock related to vested restricted stock units and recent brokered transactions.
The excerpt lists 17,666 shares associated with RSU vesting on 06/05/2026 and brokered sales by Harry Kovelman of 11,536 shares on 05/28/2026 and 20,464 shares on 05/27/2026. The broker-dealer shown is Morgan Stanley Smith Barney LLC.
Myomo, Inc. reported a Form 144 notice relating to proposed sales tied to the vesting of restricted stock units. The filing lists 16,666 shares of Common Stock associated with RSU vesting on 06/08/2026 and shows 90,231 shares of Common Stock referenced under "Securities Sold During The Past 3 Months" with the same date.
MYOMO, INC. director F. Kirk reported an open-market purchase of 25,000 shares of Common Stock on May 28, 2026 at $0.993 per share. The shares were bought in multiple lots at this price. Following the transaction, his direct holdings increased to 653,863 shares.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported open-market sales of company common stock over two days. He sold 20,464 shares on May 27, 2026 at a weighted average price of $1.002 per share and 11,536 shares on May 28, 2026 at a weighted average price of $1.0172 per share. After these transactions, he continued to hold 108,618 shares directly.
Rule 144 notice filed to sell Common stock. The filing lists 11,536 shares of Common stock as securities to be sold on 06/28/2025 classified as Restricted Stock and names Morgan Stanley Smith Barney LLC as the broker. The filing also records a past sale of 20,464 shares by Harry Kovelman on 05/27/2026.